C4X Discovery's (LON:C4XD) Clive Dix talks Proactive London's Andrew Scott through its interim results to January 2020.
Dix says its NRF-2 activator programme for sickle cell disease and pulmonary arterial hypertension is progressing and it is down to a short-list of three molecules.
Meanwhile he says that their high-value, early-stage drug candidate designed to inhibit interleukin-17, has shown early encouraging signs in inflammation.